{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T01:24:51Z","timestamp":1743643491531,"version":"3.37.3"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shandong Provincial Postdoctoral Innovation Project","award":["201903077"],"award-info":[{"award-number":["201903077"]}]},{"name":"Xuzhou Medical University Affiliated Hospital Development Fund Project","award":["XYFM20200031"],"award-info":[{"award-number":["XYFM20200031"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2018PH014"],"award-info":[{"award-number":["ZR2018PH014"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Traditional Chinese Medicine Science and Technology Development Plan Project","award":["2017-472"],"award-info":[{"award-number":["2017-472"]}]},{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","award":["2017WS133"],"award-info":[{"award-number":["2017WS133"]}],"id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Linyi People's Hospital Doctoral Fund Project","award":["2016LYBS13"],"award-info":[{"award-number":["2016LYBS13"]}]},{"name":"Shandong Key Laboratory on Hematoimmunology Open project","award":["2019XYKF009"],"award-info":[{"award-number":["2019XYKF009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06131-x","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:26:54Z","timestamp":1733718414000},"page":"5085-5101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in epigenetic therapies for B-cell non-hodgkin lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Weiwen","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liudi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"5","key":"6131_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","volume":"10","author":"M Jiang","year":"2017","unstructured":"Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: B-cell non-hodgkin lymphomas. Expert Rev Hematol 10(5):405\u2013415. https:\/\/doi.org\/10.1080\/17474086.2017.1318053","journal-title":"Expert Rev Hematol"},{"key":"6131_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-13150-4_1","volume":"165","author":"BC Chiu","year":"2015","unstructured":"Chiu BC, Hou N (2015) Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res 165:1\u201325. https:\/\/doi.org\/10.1007\/978-3-319-13150-4_1","journal-title":"Cancer Treat Res"},{"issue":"10438","key":"6131_CR3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M (2024) B-cell non-hodgkin lymphomas. Lancet 403(10438):1791\u20131807. https:\/\/doi.org\/10.1016\/S0140-6736(23)02705-8","journal-title":"Lancet"},{"key":"6131_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","volume":"42","author":"AG Solimando","year":"2016","unstructured":"Solimando AG, Ribatti D, Vacca A, Einsele H (2016) Targeting B-cell non Hodgkin lymphoma: New and old tricks. Leuk Res 42:93\u2013104. https:\/\/doi.org\/10.1016\/j.leukres.2015.11.001","journal-title":"Leuk Res"},{"issue":"12","key":"6131_CR5","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732. https:\/\/doi.org\/10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"issue":"15","key":"6131_CR6","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German Study Group Hematology and Oncology Study. J Clin Oncol 25(15):1986\u20131992. https:\/\/doi.org\/10.1200\/JCO.2006.06.4618","journal-title":"J Clin Oncol"},{"key":"6131_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/CMAR.S400013","volume":"15","author":"J Zhang","year":"2023","unstructured":"Zhang J, Gu Y, Chen B (2023) Drug-resistance mechanism and new targeted drugs and treatments of Relapse and Refractory DLBCL. Cancer Manag Res 15:245\u2013255 Published 2023 Feb 25. https:\/\/doi.org\/10.2147\/CMAR.S400013","journal-title":"Cancer Manag Res"},{"key":"6131_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-981-15-3449-2_1","volume":"1253","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lu Q, Chang C (2020) Epigenetics in Health and Disease. Adv Exp Med Biol 1253:3\u201355. https:\/\/doi.org\/10.1007\/978-981-15-3449-2_1","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"6131_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molcel.2017.10.030","volume":"69","author":"ZH Harvey","year":"2018","unstructured":"Harvey ZH, Chen Y, Jarosz DF (2018) Protein-based inheritance: Epigenetics beyond the chromosome. Mol Cell 69(2):195\u2013202. https:\/\/doi.org\/10.1016\/j.molcel.2017.10.030","journal-title":"Mol Cell"},{"issue":"6","key":"6131_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1042\/EBC20190031","volume":"63","author":"PP Law","year":"2019","unstructured":"Law PP, Holland ML (2019) DNA methylation at the crossroads of gene and environment interactions. Essays Biochem 63(6):717\u2013726. https:\/\/doi.org\/10.1042\/EBC20190031","journal-title":"Essays Biochem"},{"issue":"1","key":"6131_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G (2013) DNA methylation and its basic function. Neuropsychopharmacology 38(1):23\u201338. https:\/\/doi.org\/10.1038\/npp.2012.112","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"6131_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7150\/ijbs.11218","volume":"11","author":"H Meng","year":"2015","unstructured":"Meng H, Cao Y, Qin J et al (2015) DNA methylation, its mediators and genome integrity. Int J Biol Sci 11(5):604\u2013617 Published 2015 Apr 8. https:\/\/doi.org\/10.7150\/ijbs.11218","journal-title":"Int J Biol Sci"},{"key":"6131_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-biochem-103019-102815","volume":"89","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhang Y (2020) Role of mammalian DNA methyltransferases in Development. Annu Rev Biochem 89:135\u2013158. https:\/\/doi.org\/10.1146\/annurev-biochem-103019-102815","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"6131_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1006\/jmbi.2000.3588","volume":"297","author":"JB Margot","year":"2000","unstructured":"Margot JB, Aguirre-Arteta AM, Di Giacco BV et al (2000) Structure and function of the mouse DNA methyltransferase gene: Dnmt1 shows a tripartite structure. J Mol Biol 297(2):293\u2013300. https:\/\/doi.org\/10.1006\/jmbi.2000.3588","journal-title":"J Mol Biol"},{"key":"6131_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-387685-0.00007-X","volume":"101","author":"F Ch\u00e9din","year":"2011","unstructured":"Ch\u00e9din F (2011) The DNMT3 family of mammalian de novo DNA methyltransferases. Prog Mol Biol Transl Sci 101:255\u2013285. https:\/\/doi.org\/10.1016\/B978-0-12-387685-0.00007-X","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"7692","key":"6131_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25477","volume":"554","author":"ZM Zhang","year":"2018","unstructured":"Zhang ZM, Lu R, Wang P et al (2018) Structural basis for DNMT3A-mediated de novo DNA methylation. Nature 554(7692):387\u2013391. https:\/\/doi.org\/10.1038\/nature25477","journal-title":"Nature"},{"issue":"6","key":"6131_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","volume":"20","author":"K Hatzi","year":"2014","unstructured":"Hatzi K, Melnick A (2014) Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med 20(6):343\u2013352. https:\/\/doi.org\/10.1016\/j.molmed.2014.03.001","journal-title":"Trends Mol Med"},{"issue":"1","key":"6131_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","volume":"247","author":"K Basso","year":"2012","unstructured":"Basso K, Dalla-Favera R (2012) Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 247(1):172\u2013183. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01112.x","journal-title":"Immunol Rev"},{"issue":"3","key":"6131_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neo.2020.01.002","volume":"22","author":"J Jiao","year":"2020","unstructured":"Jiao J, Lv Z, Zhang P et al (2020) AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines. Neoplasia 22(3):142\u2013153. https:\/\/doi.org\/10.1016\/j.neo.2020.01.002","journal-title":"Neoplasia"},{"key":"6131_CR20","doi-asserted-by":"publisher","first-page":"100285","DOI":"10.1016\/j.jbc.2021.100285","volume":"296","author":"K Lopusna","year":"2021","unstructured":"Lopusna K, Nowialis P, Opavska J et al (2021) Decreases in different Dnmt3b activities drive distinct development of hematologic malignancies in mice. J Biol Chem 296:100285. https:\/\/doi.org\/10.1016\/j.jbc.2021.100285","journal-title":"J Biol Chem"},{"key":"6131_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2017.02.012","volume":"57","author":"R Frazzi","year":"2017","unstructured":"Frazzi R, Zanetti E, Pistoni M et al (2017) Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma. Leuk Res 57:89\u201396. https:\/\/doi.org\/10.1016\/j.leukres.2017.02.012","journal-title":"Leuk Res"},{"key":"6131_CR22","doi-asserted-by":"publisher","first-page":"1392391","DOI":"10.3389\/fcell.2024.1392391","volume":"12","author":"R Frazzi","year":"2024","unstructured":"Frazzi R (2024) KLF4 is an epigenetically modulated, context-dependent tumor suppressor. Front Cell Dev Biol 12:1392391 Published 2024 Jul 29. https:\/\/doi.org\/10.3389\/fcell.2024.1392391","journal-title":"Front Cell Dev Biol"},{"doi-asserted-by":"publisher","unstructured":"Yang J, Liu Y, Geng Q, Wang B (2024) Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers [published correction appears in Mol Biol Rep.;51(1):846. doi: 10.1007\/s11033-024-09709-w]. Mol Biol Rep. 2024;51(1):670. Published 2024 May 24. https:\/\/doi.org\/10.1007\/s11033-024-09240-y","key":"6131_CR23","DOI":"10.1007\/s11033-024-09240-y"},{"issue":"1","key":"6131_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/or.2021.8221","volume":"47","author":"R Frazzi","year":"2022","unstructured":"Frazzi R, Cusenza VY, Pistoni M et al (2022) KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. Oncol Rep 47(1):10. https:\/\/doi.org\/10.3892\/or.2021.8221","journal-title":"Oncol Rep"},{"key":"6131_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/978-3-031-11454-0_13","volume":"1389","author":"DJ Weisenberger","year":"2022","unstructured":"Weisenberger DJ, Lakshminarasimhan R, Liang G (2022) The role of DNA methylation and DNA methyltransferases in Cancer. Adv Exp Med Biol 1389:317\u2013348. https:\/\/doi.org\/10.1007\/978-3-031-11454-0_13","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"6131_CR26","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2013-07-509885","volume":"123","author":"N Chambwe","year":"2014","unstructured":"Chambwe N, Kormaksson M, Geng H et al (2014) Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood 123(11):1699\u20131708. https:\/\/doi.org\/10.1182\/blood-2013-07-509885","journal-title":"Blood"},{"doi-asserted-by":"publisher","unstructured":"Pan H, Jiang Y, Boi M et al (2015) Epigenomic evolution in diffuse large B-cell lymphomas. Nat Commun.;6:6921. Published 2015 Apr 20. https:\/\/doi.org\/10.1038\/ncomms7921","key":"6131_CR27","DOI":"10.1038\/ncomms7921"},{"issue":"1","key":"6131_CR28","doi-asserted-by":"publisher","first-page":"e1003137","DOI":"10.1371\/journal.pgen.1003137","volume":"9","author":"S De","year":"2013","unstructured":"De S, Shaknovich R, Riester M et al (2013) Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet 9(1):e1003137. https:\/\/doi.org\/10.1371\/journal.pgen.1003137","journal-title":"PLoS Genet"},{"issue":"2","key":"6131_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/08880018.2018.1467986","volume":"35","author":"\u0130 \u00d6zdemir","year":"2018","unstructured":"\u00d6zdemir \u0130, P\u0131narl\u0131 FG, P\u0131narl\u0131 FA et al (2018) Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas. Pediatr Hematol Oncol 35(2):131\u2013144. https:\/\/doi.org\/10.1080\/08880018.2018.1467986","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"6131_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bjh.17193","volume":"193","author":"R Dugge","year":"2021","unstructured":"Dugge R, Wagener R, M\u04e7ller P, Barth TFE (2021) Genome-wide DNA methylation analysis along the progression of gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type. Br J Haematol 193(2):369\u2013374. https:\/\/doi.org\/10.1111\/bjh.17193","journal-title":"Br J Haematol"},{"issue":"4","key":"6131_CR31","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1007\/s11033-019-04856-x","volume":"46","author":"SA Shawky","year":"2019","unstructured":"Shawky SA, El-Borai MH, Khaled HM et al (2019) The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma. Mol Biol Rep 46(4):4063\u20134076. https:\/\/doi.org\/10.1007\/s11033-019-04856-x","journal-title":"Mol Biol Rep"},{"doi-asserted-by":"publisher","unstructured":"Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN, Orlov YL, Seregina OB (2019) Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma. BMC Med Genomics.;12(Suppl 2):35. Published 2019 Mar 13. https:\/\/doi.org\/10.1186\/s12920-019-0484-9","key":"6131_CR32","DOI":"10.1186\/s12920-019-0484-9"},{"issue":"3","key":"6131_CR33","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s12253-019-00600-9","volume":"25","author":"G Mohamed","year":"2019","unstructured":"Mohamed G, Talima S, Li L et al (2019) Low expression and promoter hypermethylation of the Tumour suppressor SLIT2, are Associated with adverse patient outcomes in diffuse large B cell lymphoma. Pathol Oncol Res 25(3):1223\u20131231. https:\/\/doi.org\/10.1007\/s12253-019-00600-9","journal-title":"Pathol Oncol Res"},{"issue":"24","key":"6131_CR34","doi-asserted-by":"publisher","first-page":"e29312","DOI":"10.1097\/MD.0000000000029312","volume":"101","author":"Y Gong","year":"2022","unstructured":"Gong Y, Zhou L, Ding L et al (2022) KIF23 is a potential biomarker of diffuse large B cell lymphoma: analysis based on bioinformatics and immunohistochemistry. Med (Baltim) 101(24):e29312 Published 2022 Jun 17. https:\/\/doi.org\/10.1097\/MD.0000000000029312","journal-title":"Med (Baltim)"},{"issue":"1","key":"6131_CR35","doi-asserted-by":"publisher","first-page":"e10040","DOI":"10.1002\/ggn2.10040","volume":"2","author":"S Katayama","year":"2021","unstructured":"Katayama S, Shiraishi K, Gorai N, Andou M (2021) A CRISPR\/Cas9-based method for targeted DNA methylation enables cancer initiation in B lymphocytes. Adv Genet (Hoboken) 2(1):e10040 Published 2021 Mar 11. https:\/\/doi.org\/10.1002\/ggn2.10040","journal-title":"Adv Genet (Hoboken)"},{"issue":"7","key":"6131_CR36","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.3390\/ijms23074021","volume":"23","author":"E Zorzan","year":"2022","unstructured":"Zorzan E, Elgendy R, Guerra G et al (2022) Hypermethylation-mediated silencing of CIDEA, MAL and PCDH17 tumour suppressor genes in Canine DLBCL: from Multi-omics analyses to mechanistic studies. Int J Mol Sci 23(7):4021. https:\/\/doi.org\/10.3390\/ijms23074021. Published 2022 Apr 5","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6131_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/vco.12395","volume":"16","author":"M Sato","year":"2018","unstructured":"Sato M, Mochizuki H, Goto-Koshino Y et al (2018) Prognostic significance of hypermethylation of death-associated protein kinase (DAPK) gene CpG island in dogs with high-grade B-cell lymphoma. Vet Comp Oncol 16(3):409\u2013415. https:\/\/doi.org\/10.1111\/vco.12395","journal-title":"Vet Comp Oncol"},{"issue":"10","key":"6131_CR38","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/annonc\/mdn374","volume":"19","author":"K Amara","year":"2008","unstructured":"Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S (2008) Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 19(10):1774\u20131786. https:\/\/doi.org\/10.1093\/annonc\/mdn374","journal-title":"Ann Oncol"},{"doi-asserted-by":"publisher","unstructured":"Zhang MY, Calin G, Deng MD, Au-Yeung RKH, Wang LQ, Chim CS (2022) Epigenetic Silencing of Tumor Suppressor lncRNA NKILA: Implication on NF-\u03baB Signaling in Non-Hodgkin\u2019s Lymphoma. Genes (Basel).;13(1):128. Published 2022 Jan 11. https:\/\/doi.org\/10.3390\/genes13010128","key":"6131_CR39","DOI":"10.3390\/genes13010128"},{"issue":"8","key":"6131_CR40","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/eji.201848025","volume":"49","author":"S Tonon","year":"2019","unstructured":"Tonon S, Mion F, Dong J et al (2019) IL-10-producing B cells are characterized by a specific methylation signature. Eur J Immunol 49(8):1213\u20131225. https:\/\/doi.org\/10.1002\/eji.201848025","journal-title":"Eur J Immunol"},{"issue":"5","key":"6131_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.chembiol.2020.02.002","volume":"27","author":"Z Qiu","year":"2020","unstructured":"Qiu Z, Lin AP, Jiang S et al (2020) MYC regulation of D2HGDH and L2HGDH influences the Epigenome and Epitranscriptome. Cell Chem Biol 27(5):538\u2013550e7. https:\/\/doi.org\/10.1016\/j.chembiol.2020.02.002","journal-title":"Cell Chem Biol"},{"key":"6131_CR42","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.yexmp.2020.104567","volume":"117","author":"C Berkel","year":"2020","unstructured":"Berkel C, Cacan E (2020) DYNLL1 is hypomethylated and upregulated in a tumor stage- and grade-dependent manner and associated with increased mortality in hepatocellular carcinoma. Exp Mol Pathol 117:104567. https:\/\/doi.org\/10.1016\/j.yexmp.2020.104567","journal-title":"Exp Mol Pathol"},{"issue":"13","key":"6131_CR43","doi-asserted-by":"publisher","first-page":"17768","DOI":"10.18632\/aging.203268","volume":"13","author":"B Cao","year":"2021","unstructured":"Cao B, Guo X, Huang L et al (2021) Methylation silencing CDH23 is a poor prognostic marker in diffuse large B-cell lymphoma. Aging 13(13):17768\u201317788. https:\/\/doi.org\/10.18632\/aging.203268","journal-title":"Aging"},{"issue":"3","key":"6131_CR44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/jnci\/djab194","volume":"114","author":"CA Garcia-Prieto","year":"2022","unstructured":"Garcia-Prieto CA, Villanueva L, Bueno-Costa A et al (2022) Epigenetic profiling and response to CD19 chimeric Antigen receptor T-Cell therapy in B-Cell malignancies. J Natl Cancer Inst 114(3):436\u2013445. https:\/\/doi.org\/10.1093\/jnci\/djab194","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6131_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.trecan.2021.12.005","volume":"8","author":"F Simonetta","year":"2022","unstructured":"Simonetta F, Bertoni F (2022) An epigenetic signature in CD19-CAR T cells predicts clinical outcome. Trends Cancer 8(2):81\u201382. https:\/\/doi.org\/10.1016\/j.trecan.2021.12.005","journal-title":"Trends Cancer"},{"issue":"6","key":"6131_CR46","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41571-020-0366-2","volume":"17","author":"P Sidaway","year":"2020","unstructured":"Sidaway P (2020) COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol 17(6):336. https:\/\/doi.org\/10.1038\/s41571-020-0366-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"6131_CR47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3892\/ijo.2020.5071","volume":"57","author":"P Katopodis","year":"2020","unstructured":"Katopodis P, Anikin V, Randeva HS et al (2020) Pan\u2013cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS\u2013CoV\u20132 infection leading to COVID-19. Int J Oncol 57(2):533\u2013539. https:\/\/doi.org\/10.3892\/ijo.2020.5071","journal-title":"Int J Oncol"},{"key":"6131_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13148-016-0245-y","volume":"8","author":"B Pera","year":"2016","unstructured":"Pera B, Tang T, Marullo R et al (2016) Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenetics 8:79 Published 2016 Jul 22. https:\/\/doi.org\/10.1186\/s13148-016-0245-y","journal-title":"Clin Epigenetics"},{"issue":"1","key":"6131_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.seminhematol.2020.11.008","volume":"58","author":"B Hill","year":"2021","unstructured":"Hill B, Jagadeesh D, Pohlman B et al (2021) A pilot clinical trial of oral tetrahydrouridine\/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Semin Hematol 58(1):35\u201344. https:\/\/doi.org\/10.1053\/j.seminhematol.2020.11.008","journal-title":"Semin Hematol"},{"issue":"8","key":"6131_CR50","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2021011679","volume":"139","author":"P Martin","year":"2022","unstructured":"Martin P, Bartlett NL, Chavez JC et al (2022) Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood 139(8):1147\u20131159. https:\/\/doi.org\/10.1182\/blood.2021011679","journal-title":"Blood"},{"issue":"2","key":"6131_CR51","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jgo.2021.10.003","volume":"13","author":"EA Brem","year":"2022","unstructured":"Brem EA, Li H, Beaven AW et al (2022) SWOG 1918: a phase II\/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-hodgkin lymphomas - aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol 13(2):258\u2013264. https:\/\/doi.org\/10.1016\/j.jgo.2021.10.003","journal-title":"J Geriatr Oncol"},{"issue":"14","key":"6131_CR52","doi-asserted-by":"publisher","first-page":"R546","DOI":"10.1016\/j.cub.2004.07.007","volume":"14","author":"CL Peterson","year":"2004","unstructured":"Peterson CL, Laniel MA (2004) Histones and histone modifications. Curr Biol 14(14):R546\u2013R551. https:\/\/doi.org\/10.1016\/j.cub.2004.07.007","journal-title":"Curr Biol"},{"issue":"6648","key":"6131_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/38444","volume":"389","author":"K Luger","year":"1997","unstructured":"Luger K, M\u00e4der AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 a resolution. Nature 389(6648):251\u2013260. https:\/\/doi.org\/10.1038\/38444","journal-title":"Nature"},{"issue":"11","key":"6131_CR54","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm3890","volume":"15","author":"P Tessarz","year":"2014","unstructured":"Tessarz P, Kouzarides T (2014) Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol 15(11):703\u2013708. https:\/\/doi.org\/10.1038\/nrm3890","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"6131_CR55","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2010.08.011","volume":"142","author":"JS Lee","year":"2010","unstructured":"Lee JS, Smith E, Shilatifard A (2010) The language of histone crosstalk. Cell 142(5):682\u2013685. https:\/\/doi.org\/10.1016\/j.cell.2010.08.011","journal-title":"Cell"},{"issue":"7","key":"6131_CR56","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2174\/1568026615666150826114359","volume":"16","author":"AY Yang","year":"2016","unstructured":"Yang AY, Kim H, Li W, Kong AN (2016) Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Curr Top Med Chem 16(7):697\u2013713. https:\/\/doi.org\/10.2174\/1568026615666150826114359","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"6131_CR57","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E (2016) HDACs and HDAC inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med 6(10):a026831. https:\/\/doi.org\/10.1101\/cshperspect.a026831. Published 2016 Oct 3","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"6131_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0959-437x(00)00173-8","volume":"11","author":"R Marmorstein","year":"2001","unstructured":"Marmorstein R, Roth SY (2001) Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev 11(2):155\u2013161. https:\/\/doi.org\/10.1016\/s0959-437x(00)00173-8","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"6131_CR59","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4132\/KoreanJPathol.2012.46.2.142","volume":"46","author":"SK Min","year":"2012","unstructured":"Min SK, Koh YH, Park Y et al (2012) Expression of HAT1 and HDAC1, 2, 3 in diffuse large B-Cell lymphomas, peripheral T-Cell lymphomas, and NK\/T-Cell Lymphomas. Korean J Pathol 46(2):142\u2013150. https:\/\/doi.org\/10.4132\/KoreanJPathol.2012.46.2.142","journal-title":"Korean J Pathol"},{"issue":"10","key":"6131_CR60","doi-asserted-by":"publisher","first-page":"994","DOI":"10.7150\/ijms.8522","volume":"11","author":"SH Lee","year":"2014","unstructured":"Lee SH, Yoo C, Im S, Jung JH, Choi HJ, Yoo J (2014) Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance. Int J Med Sci 11(10):994\u20131000 Published 2014 Jul 17. https:\/\/doi.org\/10.7150\/ijms.8522","journal-title":"Int J Med Sci"},{"key":"6131_CR61","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.2147\/OTT.S142974","volume":"10","author":"XJ Lin","year":"2017","unstructured":"Lin XJ, Cai LM, Qian ZJ et al (2017) Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma. Onco Targets Ther 10:5129\u20135136 Published 2017 Oct 24. https:\/\/doi.org\/10.2147\/OTT.S142974","journal-title":"Onco Targets Ther"},{"issue":"6","key":"6131_CR62","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"Green MR (2018) Chromatin modifying gene mutations in follicular lymphoma. Blood 131(6):595\u2013604. https:\/\/doi.org\/10.1182\/blood-2017-08-737361","journal-title":"Blood"},{"issue":"1","key":"6131_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","volume":"6","author":"YH Huang","year":"2021","unstructured":"Huang YH, Cai K, Xu PP et al (2021) CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis. Signal Transduct Target Ther 6(1):10. https:\/\/doi.org\/10.1038\/s41392-020-00437-8. Published 2021 Jan 11","journal-title":"Signal Transduct Target Ther"},{"key":"6131_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/BTT.S29965","volume":"7","author":"K Ververis","year":"2013","unstructured":"Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47\u201360. https:\/\/doi.org\/10.2147\/BTT.S29965","journal-title":"Biologics"},{"issue":"10","key":"6131_CR65","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/bloodadvances.202000356","volume":"5","author":"AA Mensah","year":"2021","unstructured":"Mensah AA, Spriano F, Sartori G et al (2021) Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Adv 5(10):2467\u20132480. https:\/\/doi.org\/10.1182\/bloodadvances.202000356","journal-title":"Blood Adv"},{"issue":"5","key":"6131_CR66","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3892\/mmr.2021.11947","volume":"23","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chi F, Qin K et al (2021) Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs\/STAT3\/Bcl\u20132 pathway. Mol Med Rep 23(5):308. https:\/\/doi.org\/10.3892\/mmr.2021.11947","journal-title":"Mol Med Rep"},{"issue":"5","key":"6131_CR67","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","volume":"22","author":"AM Evens","year":"2016","unstructured":"Evens AM, Balasubramanian S, Vose JM et al (2016) A phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in Relapsed\/Refractory lymphoma. Clin Cancer Res 22(5):1059\u20131066. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0624","journal-title":"Clin Cancer Res"},{"doi-asserted-by":"publisher","unstructured":"Zhang MC, Fang Y, Wang L et al (2020) Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Clin Epigenetics.;12(1):160. Published 2020 Oct 23. https:\/\/doi.org\/10.1186\/s13148-020-00948-9","key":"6131_CR68","DOI":"10.1186\/s13148-020-00948-9"},{"doi-asserted-by":"publisher","unstructured":"Guan XW, Wang HQ, Ban WW et al (2020) Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis.;11(1):20. Published 2020 Jan 6. https:\/\/doi.org\/10.1038\/s41419-019-2210-0","key":"6131_CR69","DOI":"10.1038\/s41419-019-2210-0"},{"issue":"12","key":"6131_CR70","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/bloodadvances.2018019240","volume":"2","author":"K Drott","year":"2018","unstructured":"Drott K, Hagberg H, Papworth K, Relander T, Jerkeman M (2018) Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). Blood Adv 2(12):1386\u20131392. https:\/\/doi.org\/10.1182\/bloodadvances.2018019240","journal-title":"Blood Adv"},{"issue":"6","key":"6131_CR71","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/bjh.16008","volume":"186","author":"SE Spurgeon","year":"2019","unstructured":"Spurgeon SE, Sharma K, Claxton DF et al (2019) Phase 1\u20132 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-hodgkin lymphoma and previously untreated mantle cell lymphoma. Br J Haematol 186(6):845\u2013854. https:\/\/doi.org\/10.1111\/bjh.16008","journal-title":"Br J Haematol"},{"doi-asserted-by":"publisher","unstructured":"van Tilburg CM, Milde T, Witt R et al (2019) Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clin Epigenetics.;11(1):188. Published 2019 Dec 10. https:\/\/doi.org\/10.1186\/s13148-019-0775-1","key":"6131_CR72","DOI":"10.1186\/s13148-019-0775-1"},{"issue":"3","key":"6131_CR73","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/10428194.2022.2164194","volume":"64","author":"D Qualls","year":"2023","unstructured":"Qualls D, Noy A, Straus D et al (2023) Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leuk Lymphoma 64(3):738\u2013741. https:\/\/doi.org\/10.1080\/10428194.2022.2164194","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6131_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00428-022-03347-y","volume":"481","author":"MM Brune","year":"2022","unstructured":"Brune MM, Vela V, Bratic Hench I et al (2022) H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas. Virchows Arch 481(3):489\u2013497. https:\/\/doi.org\/10.1007\/s00428-022-03347-y","journal-title":"Virchows Arch"},{"issue":"5","key":"6131_CR75","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1074\/jbc.RA119.008742","volume":"295","author":"V Karkhanis","year":"2020","unstructured":"Karkhanis V, Alinari L, Ozer HG et al (2020) Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. J Biol Chem 295(5):1165\u20131180. https:\/\/doi.org\/10.1074\/jbc.RA119.008742","journal-title":"J Biol Chem"},{"issue":"13","key":"6131_CR76","doi-asserted-by":"publisher","first-page":"e00273","DOI":"10.1128\/JVI.00273-19","volume":"93","author":"RC Vargas-Ayala","year":"2019","unstructured":"Vargas-Ayala RC, Jay A, Manara F et al (2019) Interplay between the Epigenetic Enzyme Lysine (K)-Specific demethylase 2B and Epstein-Barr Virus infection. J Virol 93(13):e00273\u2013e00219 Published 2019 Jun 14. https:\/\/doi.org\/10.1128\/JVI.00273-19","journal-title":"J Virol"},{"issue":"4","key":"6131_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris WJ, Huang X, Lynch JT et al (2012) The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells [published correction appears in Cancer Cell. 2012;21(6):856]. Cancer Cell 21(4):473\u2013487. https:\/\/doi.org\/10.1016\/j.ccr.2012.03.014","journal-title":"Cancer Cell"},{"issue":"1","key":"6131_CR78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","volume":"28","author":"HP Mohammad","year":"2015","unstructured":"Mohammad HP, Smitheman KN, Kamat CD et al (2015) A DNA hypomethylation signature predicts Antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 28(1):57\u201369. https:\/\/doi.org\/10.1016\/j.ccell.2015.06.002","journal-title":"Cancer Cell"},{"issue":"10","key":"6131_CR79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12032-021-01572-0","volume":"38","author":"H Liu","year":"2021","unstructured":"Liu H, Wei J, Sang N et al (2021) The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy. Med Oncol 38(10):124 Published 2021 Sep 7. https:\/\/doi.org\/10.1007\/s12032-021-01572-0","journal-title":"Med Oncol"},{"doi-asserted-by":"publisher","unstructured":"Heyn H, Vidal E, Ferreira HJ et al (2016) Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer. Genome Biol.;17:11. Published 2016 Jan 26. https:\/\/doi.org\/10.1186\/s13059-016-0879-2","key":"6131_CR80","DOI":"10.1186\/s13059-016-0879-2"},{"issue":"5","key":"6131_CR81","first-page":"2174","volume":"11","author":"M De Martino","year":"2021","unstructured":"De Martino M, Nicolau-Neto P, Ribeiro Pinto LF et al (2021) HMGA1 induces EZH2 overexpression in human B-cell lymphomas. Am J Cancer Res 11(5):2174\u20132187 Published 2021 May 15","journal-title":"Am J Cancer Res"},{"issue":"10","key":"6131_CR82","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K (2023) An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood 141(10):1159\u20131168. https:\/\/doi.org\/10.1182\/blood.2022016862","journal-title":"Blood"},{"issue":"20","key":"6131_CR83","doi-asserted-by":"publisher","first-page":"15170","DOI":"10.1021\/acs.jmedchem.1c01154","volume":"64","author":"B Zhou","year":"2021","unstructured":"Zhou B, Liang X, Mei H et al (2021) Discovery of IHMT-EZH2-115 as a potent and selective enhancer of Zeste Homolog 2 (EZH2) inhibitor for the treatment of B-Cell lymphomas. J Med Chem 64(20):15170\u201315188. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01154","journal-title":"J Med Chem"},{"issue":"7","key":"6131_CR84","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","volume":"9","author":"Y Song","year":"2022","unstructured":"Song Y, Liu Y, Li ZM, Li L, Su H, Jin Z, Zuo X, Wu J, Zhou H, Li K, He C, Zhou J, Qi J, Hao S, Cai Z, Li Y, Wang W, Zhang X, Zou J, Zhu J (2022) SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol 9(7):e493\u2013e503. https:\/\/doi.org\/10.1016\/S2352-3026(22)00134-X","journal-title":"Lancet Haematol"},{"issue":"24","key":"6131_CR85","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","volume":"25","author":"TA Yap","year":"2019","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Dumitrescu P, Wang T, Frey X, Carver S, Horner J, Oh T, Khaled C, Dhar A, A., Johnson PWM (2019) Phase I study of the Novel enhancer of Zeste Homolog 2 (EZH2) inhibitor GSK2816126 in patients with Advanced Hematologic and solid tumors. Clin cancer Research: Official J Am Association Cancer Res 25(24):7331\u20137339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4121","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"4","key":"6131_CR86","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-021-01494-w","volume":"36","author":"J Yang","year":"2022","unstructured":"Yang J, Weisberg EL, Qi S et al (2022) Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia 36(4):1048\u20131057. https:\/\/doi.org\/10.1038\/s41375-021-01494-w","journal-title":"Leukemia"},{"issue":"3","key":"6131_CR87","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3892\/or.2019.7240","volume":"42","author":"G Dominguez-Gomez","year":"2019","unstructured":"Dominguez-Gomez G, Cortez-Pedroza D, Chavez-Blanco A et al (2019) Growth inhibition and transcriptional effects of Ribavirin in lymphoma. Oncol Rep 42(3):1248\u20131256. https:\/\/doi.org\/10.3892\/or.2019.7240","journal-title":"Oncol Rep"},{"issue":"5","key":"6131_CR88","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano A, Soria JC, Toulmonde M et al (2018) Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 19(5):649\u2013659. https:\/\/doi.org\/10.1016\/S1470-2045(18)30145-1","journal-title":"Lancet Oncol"},{"issue":"3","key":"6131_CR89","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/cas.14822","volume":"112","author":"W Munakata","year":"2021","unstructured":"Munakata W, Shirasugi Y, Tobinai K et al (2021) Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci 112(3):1123\u20131131. https:\/\/doi.org\/10.1111\/cas.14822","journal-title":"Cancer Sci"},{"issue":"11","key":"6131_CR90","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A et al (2020) Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21(11):1433\u20131442. https:\/\/doi.org\/10.1016\/S1470-2045(20)30441-1","journal-title":"Lancet Oncol"},{"issue":"7","key":"6131_CR91","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","volume":"22","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Cartron G, Popplewell L et al (2022) Combination of Atezolizumab and Tazemetostat in patients with Relapsed\/Refractory diffuse large B-Cell lymphoma: results from a phase ib study. Clin Lymphoma Myeloma Leuk 22(7):504\u2013512. https:\/\/doi.org\/10.1016\/j.clml.2021.12.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"6131_CR92","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","volume":"26","author":"C Sarkozy","year":"2020","unstructured":"Sarkozy C, Morschhauser F, Dubois S et al (2020) A LYSA phase ib study of Tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma (DLBCL) with poor prognosis features. Clin Cancer Res 26(13):3145\u20133153. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3741","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6131_CR93","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281\u2013297. https:\/\/doi.org\/10.1016\/s0092-8674(04)00045-5","journal-title":"Cell"},{"issue":"4","key":"6131_CR94","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1139\/bcb-2019-0336","volume":"98","author":"C He","year":"2020","unstructured":"He C, Yang J, Ding J et al (2020) MiR-448 targets BLC2 and inhibits the growth of pituitary adenoma cells. Biochem Cell Biol 98(4):511\u2013517. https:\/\/doi.org\/10.1139\/bcb-2019-0336","journal-title":"Biochem Cell Biol"},{"issue":"5","key":"6131_CR95","doi-asserted-by":"publisher","first-page":"BSR20182321","DOI":"10.1042\/BSR20182321","volume":"39","author":"HW Cui","year":"2019","unstructured":"Cui HW, Han WY, Hou LN, Yang L, Li X, Su XL (2019) Mir-1915-3p inhibits Bcl-2 expression in the development of gastric cancer. Biosci Rep 39(5):BSR20182321 Published 2019 May 15. https:\/\/doi.org\/10.1042\/BSR20182321","journal-title":"Biosci Rep"},{"issue":"6","key":"6131_CR96","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/CAD.0000000000001282","volume":"33","author":"X Chang","year":"2022","unstructured":"Chang X, Jian L (2022) LncRNA ZFPM2-AS1 drives the progression of nasopharyngeal carcinoma via modulating the downstream miR-3612\/DTL signaling. Anticancer Drugs 33(6):523\u2013533. https:\/\/doi.org\/10.1097\/CAD.0000000000001282","journal-title":"Anticancer Drugs"},{"issue":"10","key":"6131_CR97","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/jcb.29650","volume":"121","author":"YJ Xu","year":"2020","unstructured":"Xu YJ, Yu H, Liu GX (2020) Hsa_circ_0031288\/hsa-miR-139-3p\/Bcl-6 regulatory feedback circuit influences the invasion and migration of cervical cancer HeLa cells. J Cell Biochem 121(10):4251\u20134260. https:\/\/doi.org\/10.1002\/jcb.29650","journal-title":"J Cell Biochem"},{"issue":"9","key":"6131_CR98","doi-asserted-by":"publisher","first-page":"16283","DOI":"10.1002\/jcb.28910","volume":"120","author":"W Zhang","year":"2019","unstructured":"Zhang W, Jiang H, Chen Y, Ren F (2019) Resveratrol chemosensitizes adriamycin-resistant breast cancer cells by modulating miR-122-5p. J Cell Biochem 120(9):16283\u201316292. https:\/\/doi.org\/10.1002\/jcb.28910","journal-title":"J Cell Biochem"},{"issue":"3","key":"6131_CR99","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2012.04.005","volume":"149","author":"MS Ebert","year":"2012","unstructured":"Ebert MS, Sharp PA (2012) Roles for microRNAs in conferring robustness to biological processes. Cell 149(3):515\u2013524. https:\/\/doi.org\/10.1016\/j.cell.2012.04.005","journal-title":"Cell"},{"issue":"2","key":"6131_CR100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215\u2013233. https:\/\/doi.org\/10.1016\/j.cell.2009.01.002","journal-title":"Cell"},{"doi-asserted-by":"publisher","unstructured":"Sun R, Zhang PP, Weng XQ et al (2022) Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40\/OX40L-mediated interaction with Th17 cells. Signal Transduct Target Ther.;7(1):80. Published 2022 Mar 18. https:\/\/doi.org\/10.1038\/s41392-022-00895-2","key":"6131_CR101","DOI":"10.1038\/s41392-022-00895-2"},{"issue":"1","key":"6131_CR102","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-019-0977-3","volume":"18","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Sun R, Zhao HJ et al (2019) MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8\u2009+\u2009T cells. Mol Cancer 18(1):54. https:\/\/doi.org\/10.1186\/s12943-019-0977-3. Published 2019 Mar 30","journal-title":"Mol Cancer"},{"issue":"5","key":"6131_CR103","doi-asserted-by":"publisher","first-page":"300060521101639","DOI":"10.1177\/03000605211016390","volume":"49","author":"J He","year":"2021","unstructured":"He J, Xi Y, Gao N, Xu E, Chang J, Liu J (2021) Identification of miRNA-34a and miRNA-155 as prognostic markers for mantle cell lymphoma. J Int Med Res 49(5):3000605211016390. https:\/\/doi.org\/10.1177\/03000605211016390","journal-title":"J Int Med Res"},{"key":"6131_CR104","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exphem.2020.07.005","volume":"88","author":"E Jab\u0142o\u0144ska","year":"2020","unstructured":"Jab\u0142o\u0144ska E, Bia\u0142opiotrowicz E, Szyd\u0142owski M, Prochorec-Sobieszek M, Juszczy\u0144ski P, Szumera-Cie\u0107kiewicz A (2020) DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells. Exp Hematol 88:56\u201367e2. https:\/\/doi.org\/10.1016\/j.exphem.2020.07.005","journal-title":"Exp Hematol"},{"key":"6131_CR105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2018.12.020","volume":"446","author":"V Labi","year":"2019","unstructured":"Labi V, Schoeler K, Melamed D (2019) miR-17\u223c92 in lymphocyte development and lymphomagenesis. Cancer Lett 446:73\u201380. https:\/\/doi.org\/10.1016\/j.canlet.2018.12.020","journal-title":"Cancer Lett"},{"issue":"7\u20138","key":"6131_CR106","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41417-018-0057-7","volume":"26","author":"QM Wang","year":"2019","unstructured":"Wang QM, Lian GY, Song Y, Peng ZD, Xu SH, Gong Y (2019) Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3\/SHP-1 in non-hodgkin lymphoma. Cancer Gene Ther 26(7\u20138):195\u2013207. https:\/\/doi.org\/10.1038\/s41417-018-0057-7","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"6131_CR107","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/08916934.2021.2023863","volume":"55","author":"D Lin","year":"2022","unstructured":"Lin D, Wang Y, Lei L, Lin C (2022) Circ_0003645 serves as mir-335-5p sponge to promote the biological process of diffuse large B-cell lymphoma by upregulating NFIB. Autoimmunity 55(2):127\u2013135. https:\/\/doi.org\/10.1080\/08916934.2021.2023863","journal-title":"Autoimmunity"},{"issue":"4","key":"6131_CR108","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s13577-020-00321-1","volume":"33","author":"R Wang","year":"2020","unstructured":"Wang R, Shen J, Su N, Wang Q, Zhang M, Liu C (2020) MiR-645 regulates the proliferation and apoptosis of diffuse large B-cell lymphoma by targeting DACH1. Hum Cell 33(4):1091\u20131098. https:\/\/doi.org\/10.1007\/s13577-020-00321-1","journal-title":"Hum Cell"},{"issue":"1","key":"6131_CR109","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3892\/or.2019.7144","volume":"42","author":"H Su","year":"2019","unstructured":"Su H, Chang J, Xu M, Sun R, Wang J (2019) CDK6 overexpression resulted from microRNA\u2013320d downregulation promotes cell proliferation in diffuse large B\u2013cell lymphoma. Oncol Rep 42(1):321\u2013327. https:\/\/doi.org\/10.3892\/or.2019.7144","journal-title":"Oncol Rep"},{"issue":"13","key":"6131_CR110","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-17-4049","volume":"78","author":"T Hu","year":"2018","unstructured":"Hu T, Chong Y, Lu S et al (2018) miR-339 promotes development of stem cell Leukemia\/Lymphoma syndrome via downregulation of the BCL2L11 and BAX proapoptotic genes. Cancer Res 78(13):3522\u20133531. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-4049","journal-title":"Cancer Res"},{"issue":"6","key":"6131_CR111","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s13258-021-01094-z","volume":"43","author":"W Liu","year":"2021","unstructured":"Liu W, Lei L, Liu X, Ye S (2021) CircRNA_OTUD7A upregulates FOXP1 expression to facilitate the progression of diffuse large B-cell lymphoma via acting as a sponge of miR-431-5p. Genes Genomics 43(6):653\u2013667. https:\/\/doi.org\/10.1007\/s13258-021-01094-z","journal-title":"Genes Genomics"},{"doi-asserted-by":"publisher","unstructured":"Wu YX, He S, Xu XH (2018) Zhonghua Xue Ye Xue Za Zhi 39(8):668\u2013673. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.08.011","key":"6131_CR112","DOI":"10.3760\/cma.j.issn.0253-2727.2018.08.011"},{"issue":"11","key":"6131_CR113","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.21037\/tcr-21-2394","volume":"10","author":"W Wu","year":"2021","unstructured":"Wu W, Chen L, Chen C, Yu L, Zheng J (2021) miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN. Transl Cancer Res 10(11):4905\u20134913. https:\/\/doi.org\/10.21037\/tcr-21-2394","journal-title":"Transl Cancer Res"},{"issue":"1","key":"6131_CR114","first-page":"89","volume":"13","author":"B Han","year":"2020","unstructured":"Han B, Wang S, Zhao H (2020) MicroRNA-21 and microRNA-155 promote the progression of Burkitt\u2019s lymphoma by the PI3K\/AKT signaling pathway. Int J Clin Exp Pathol 13(1):89\u201398 Published 2020 Jan 1","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"6131_CR115","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","volume":"33","author":"E Anastasiadou","year":"2019","unstructured":"Anastasiadou E, Stroopinsky D, Alimperti S et al (2019) Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33(1):132\u2013147. https:\/\/doi.org\/10.1038\/s41375-018-0178-x","journal-title":"Leukemia"},{"doi-asserted-by":"publisher","unstructured":"Zhang MY, Wang LQ, Chim CS (2021) miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin\u2019s lymphoma: novel targets with impact on ERK signaling and cell migration. Cell Commun Signal.;19(1):62. Published 2021 May 27. https:\/\/doi.org\/10.1186\/s12964-021-00707-0","key":"6131_CR116","DOI":"10.1186\/s12964-021-00707-0"},{"doi-asserted-by":"publisher","unstructured":"Xu Y, Liu Z, Lv L et al (2020) MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8 T lymphocytes in human diffuse large B cell lymphoma. J Exp Clin Cancer Res.;39(1):238. Published 2020 Nov 10. https:\/\/doi.org\/10.1186\/s13046-020-01752-2+","key":"6131_CR117","DOI":"10.1186\/s13046-020-01752-2+"},{"doi-asserted-by":"publisher","unstructured":"Zhao CC, Jiao Y, Zhang YY et al (2019) Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt\/\u03b2-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis.;10(4):252. Published 2019 Mar 15. https:\/\/doi.org\/10.1038\/s41419-019-1479-3","key":"6131_CR118","DOI":"10.1038\/s41419-019-1479-3"},{"key":"6131_CR119","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2021.08.010","volume":"103","author":"J Yuan","year":"2021","unstructured":"Yuan J, Zhang Q, Wu S et al (2021) miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK\/Nf-\u03bab signaling pathway in mantle cell lymphoma. Exp Hematol 103:52\u201359e2. https:\/\/doi.org\/10.1016\/j.exphem.2021.08.010","journal-title":"Exp Hematol"},{"doi-asserted-by":"publisher","unstructured":"Zhang Q, Zhang WT, Wu SS et al (2018) Zhonghua Xue Ye Xue Za Zhi 39(7):579\u2013583. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.07.010","key":"6131_CR120","DOI":"10.3760\/cma.j.issn.0253-2727.2018.07.010"},{"key":"6131_CR121","doi-asserted-by":"publisher","first-page":"106653","DOI":"10.1016\/j.leukres.2021.106653","volume":"110","author":"L An","year":"2021","unstructured":"An L, Li X, Yang J (2021) MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12. Leuk Res 110:106653. https:\/\/doi.org\/10.1016\/j.leukres.2021.106653","journal-title":"Leuk Res"},{"issue":"7","key":"6131_CR122","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.7150\/thno.53561","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, He X, Gan Y et al (2021) Targeting miR-21 with NL101 blocks c-Myc\/Mxd1 loop and inhibits the growth of B cell lymphoma. Theranostics 11(7):3439\u20133451 Published 2021 Jan 19. https:\/\/doi.org\/10.7150\/thno.53561","journal-title":"Theranostics"},{"doi-asserted-by":"publisher","unstructured":"Zhang MY, Calin GA, Yuen KS, Jin DY, Chim CS (2020) Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. Clin Epigenetics.;12(1):150. Published 2020 Oct 19. https:\/\/doi.org\/10.1186\/s13148-020-00926-1","key":"6131_CR123","DOI":"10.1186\/s13148-020-00926-1"},{"issue":"23","key":"6131_CR124","doi-asserted-by":"publisher","first-page":"12063","DOI":"10.26355\/eurrev_202012_23995","volume":"24","author":"WJ Zhang","year":"2020","unstructured":"Zhang WJ, Chen FF, Wang YQ, Yu W, Dong FL, Zhuang HX (2020) MiR-150 inhibits proliferation of mantle-cell lymphoma cells via regulation of MET. Eur Rev Med Pharmacol Sci 24(23):12063\u201312072. https:\/\/doi.org\/10.26355\/eurrev_202012_23995","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6131_CR125","doi-asserted-by":"publisher","first-page":"9832956","DOI":"10.1155\/2019\/9832956","volume":"2019","author":"D Zhu","year":"2019","unstructured":"Zhu D, Fang C, He W, Wu C, Li X, Wu J (2019) MicroRNA-181a inhibits activated B-Cell-Like diffuse large B-Cell lymphoma progression by repressing CARD11. J Oncol 2019:9832956 Published 2019 Sep 24. https:\/\/doi.org\/10.1155\/2019\/9832956","journal-title":"J Oncol"},{"doi-asserted-by":"publisher","unstructured":"Lu J, Huang X, Wang L, Li Y (2022) MiR-181b inhibits the proliferation of Lymphoma Rajixi Cell line by regulating the expression of Target Gene FAMLF. Cell Mol Biol (Noisy-le-grand). 67(6):11\u201317 Published 2022 Feb 27. https:\/\/doi.org\/10.14715\/cmb\/2021.67.6.2","key":"6131_CR126","DOI":"10.14715\/cmb\/2021.67.6.2"},{"issue":"8","key":"6131_CR127","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1080\/10428194.2021.1894642","volume":"62","author":"Y Gao","year":"2021","unstructured":"Gao Y, Ding X (2021) Mir-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1\/STAT3\/AKT pathway. Leuk Lymphoma 62(8):1884\u20131891. https:\/\/doi.org\/10.1080\/10428194.2021.1894642","journal-title":"Leuk Lymphoma"},{"key":"6131_CR128","doi-asserted-by":"publisher","first-page":"106769","DOI":"10.1016\/j.leukres.2021.106769","volume":"112","author":"Y Wang","year":"2022","unstructured":"Wang Y, Guo D, Li B et al (2022) MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1). Leuk Res 112:106769. https:\/\/doi.org\/10.1016\/j.leukres.2021.106769","journal-title":"Leuk Res"},{"issue":"6","key":"6131_CR129","doi-asserted-by":"publisher","first-page":"935","DOI":"10.7150\/ijbs.40756","volume":"16","author":"SH Liu","year":"2020","unstructured":"Liu SH, Wang PP, Chen CT et al (2020) MicroRNA-148b enhances the radiosensitivity of B-cell lymphoma cells by targeting Bcl-w to promote apoptosis. Int J Biol Sci 16(6):935\u2013946 Published 2020 Jan 23. https:\/\/doi.org\/10.7150\/ijbs.40756","journal-title":"Int J Biol Sci"},{"key":"6131_CR130","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s11658-019-0190-9","volume":"24","author":"JR Sun","year":"2019","unstructured":"Sun JR, Zhang X, Zhang Y (2019) MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1. Cell Mol Biol Lett 24:68 Published 2019 Dec 4. https:\/\/doi.org\/10.1186\/s11658-019-0190-9","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"6131_CR131","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4274\/balkanmedj.galenos.2020.2020.8-23","volume":"38","author":"Y Li","year":"2021","unstructured":"Li Y, Qian J, Yang L (2021) Inhibition of YBX1 by miR-216a suppresses Proliferation and Invasion of diffuse large B-Cell lymphoma. Balkan Med J 38(3):171\u2013176. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2020.2020.8-23","journal-title":"Balkan Med J"},{"issue":"11","key":"6131_CR132","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00210-020-01834-0","volume":"393","author":"B Wu","year":"2020","unstructured":"Wu B, Li J, Wang H, Wu Q, Liu H (2020) MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11. Naunyn Schmiedebergs Arch Pharmacol 393(11):2197\u20132208. https:\/\/doi.org\/10.1007\/s00210-020-01834-0","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"6131_CR133","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.bbrc.2018.12.055","volume":"508","author":"XW Zhu","year":"2019","unstructured":"Zhu XW, Wang J, Zhu MX, Wang YF, Yang SY, Ke XY (2019) MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7H3. Biochem Biophys Res Commun 508(4):1067\u20131073. https:\/\/doi.org\/10.1016\/j.bbrc.2018.12.055","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"6131_CR134","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/CAD.0000000000000656","volume":"29","author":"W Li","year":"2018","unstructured":"Li W, Xue W, Wang X et al (2018) MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7\/CCL21 pair. Anticancer Drugs 29(9):861\u2013870. https:\/\/doi.org\/10.1097\/CAD.0000000000000656","journal-title":"Anticancer Drugs"},{"issue":"2","key":"6131_CR135","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3892\/or.2020.7901","volume":"45","author":"J Fu","year":"2021","unstructured":"Fu J, Lou X, Wan S et al (2021) microRNA\u2013196a\u20133p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B\u2013cell lymphoma. Oncol Rep 45(2):764\u2013775. https:\/\/doi.org\/10.3892\/or.2020.7901","journal-title":"Oncol Rep"},{"issue":"1","key":"6131_CR136","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3892\/or.2018.6821","volume":"41","author":"Y Huang","year":"2019","unstructured":"Huang Y, Zou Y, Lin L, Ma X, Zheng R (2019) miR\u2013101 regulates the cell proliferation and apoptosis in diffuse large B\u2013cell lymphoma by targeting MEK1 via regulation of the ERK\/MAPK signaling pathway. Oncol Rep 41(1):377\u2013386. https:\/\/doi.org\/10.3892\/or.2018.6821","journal-title":"Oncol Rep"},{"issue":"1","key":"6131_CR137","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13287-023-03373-w","volume":"14","author":"X Zhao","year":"2023","unstructured":"Zhao X, Xu M, Hu X et al (2023) Human bone marrow-derived mesenchymal stem overexpressing microRNA-124-3p inhibit DLBCL progression by downregulating the NFATc1\/cMYC pathway. Stem Cell Res Ther 14(1):148. https:\/\/doi.org\/10.1186\/s13287-023-03373-w. Published 2023 May 29","journal-title":"Stem Cell Res Ther"},{"doi-asserted-by":"publisher","unstructured":"Xie Y, Tan L, Li YT, Zeng Y, Zhongguo Shi Y (2020) Xue Ye Xue Za Zhi 28(5):1578\u20131584. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.05.025","key":"6131_CR138","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.05.025"},{"doi-asserted-by":"publisher","unstructured":"Wu RJ, Zou Y, Ma XD, Zheng RJ, Zhongguo Shi Y (2020) Xue Ye Xue Za Zhi 28(5):1570\u20131577. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.05.024","key":"6131_CR139","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.05.024"},{"issue":"20","key":"6131_CR140","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.3390\/cancers14205031","volume":"14","author":"J Menegatti","year":"2022","unstructured":"Menegatti J, Nakel J, Stepanov YK et al (2022) Changes of protein expression after CRISPR\/Cas9 knockout of miRNA-142 in cell lines derived from diffuse large B-Cell lymphoma. Cancers (Basel) 14(20):5031. https:\/\/doi.org\/10.3390\/cancers14205031. Published 2022 Oct 14","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6131_CR141","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/cells13010084","volume":"13","author":"W Huang","year":"2023","unstructured":"Huang W, Paul D, Calin GA, Bayraktar R (2023) miR-142: a Master Regulator in Hematological malignancies and Therapeutic opportunities. Cells 13(1):84. https:\/\/doi.org\/10.3390\/cells13010084PMID: 38201290; PMCID: PMC10778542","journal-title":"Cells"},{"key":"6131_CR142","doi-asserted-by":"publisher","first-page":"12375","DOI":"10.2147\/CMAR.S270374","volume":"12","author":"H Zhou","year":"2020","unstructured":"Zhou H, Tang H, Li N et al (2020) MicroRNA-361-3p inhibit the Progression of Lymphoma by the Wnt\/\u03b2-Catenin signaling pathway. Cancer Manag Res 12:12375\u201312384 Published 2020 Dec 2. https:\/\/doi.org\/10.2147\/CMAR.S270374","journal-title":"Cancer Manag Res"},{"issue":"5","key":"6131_CR143","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.sjbs.2018.05.010","volume":"25","author":"W Wang","year":"2018","unstructured":"Wang W, Lin P, Yao H, Jia X, Sun J, Feng L (2018) MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma. Saudi J Biol Sci 25(5):982\u2013985. https:\/\/doi.org\/10.1016\/j.sjbs.2018.05.010","journal-title":"Saudi J Biol Sci"},{"issue":"7","key":"6131_CR144","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/s41375-022-01565-6","volume":"36","author":"W Zhou","year":"2022","unstructured":"Zhou W, Xu Y, Zhang J et al (2022) MiRNA-363-3p\/DUSP10\/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma. Leukemia 36(7):1861\u20131869. https:\/\/doi.org\/10.1038\/s41375-022-01565-6","journal-title":"Leukemia"},{"issue":"1","key":"6131_CR145","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-020-01752-2","volume":"39","author":"Y Xu","year":"2020","unstructured":"Xu Y, Liu Z, Lv L et al (2020) MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8\u2009+\u2009T lymphocytes in human diffuse large B cell lymphoma. J Exp Clin Cancer Res 39(1):238. https:\/\/doi.org\/10.1186\/s13046-020-01752-2. Published 2020 Nov 10","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"6131_CR146","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41419-019-1886-5","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Liu Y, Zhang J, Liu Y, Qi Q (2019) LncRNA SNHG14\/miR-5590-3p\/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1\/PD-L1 checkpoint. Cell Death Dis 10(10):731 Published 2019 Sep 30. https:\/\/doi.org\/10.1038\/s41419-019-1886-5","journal-title":"Cell Death Dis"},{"key":"6131_CR147","doi-asserted-by":"publisher","first-page":"735855","DOI":"10.3389\/fcell.2021.735855","volume":"9","author":"W Zheng","year":"2021","unstructured":"Zheng W, Lai G, Lin Q, Issah MA, Fu H, Shen J (2021) A miR-129-5P\/ARID3A negative feedback Loop modulates diffuse large B cell lymphoma progression and Immune Evasion through regulating the PD-1\/PD-L1 checkpoint. Front Cell Dev Biol 9:735855 Published 2021 Oct 27. https:\/\/doi.org\/10.3389\/fcell.2021.735855","journal-title":"Front Cell Dev Biol"},{"key":"6131_CR148","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopha.2018.08.151","volume":"108","author":"R Wang","year":"2018","unstructured":"Wang R, Shen J, Wang Q, Zhang M (2018) Bortezomib inhibited the progression of diffuse large B-cell lymphoma via targeting miR-198. Biomed Pharmacother 108:43\u201349. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.151","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"6131_CR149","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","volume":"27","author":"E Anastasiadou","year":"2021","unstructured":"Anastasiadou E, Seto AG, Beatty X et al (2021) Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL Tumor Cell Growth in Vitro and in vivo. Clin Cancer Res 27(4):1139\u20131149. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3139","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6131_CR150","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12185-012-1256-x","volume":"97","author":"H Bai","year":"2013","unstructured":"Bai H, Wei J, Deng C, Yang X, Wang C, Xu R (2013) MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 97(2):223\u2013231. https:\/\/doi.org\/10.1007\/s12185-012-1256-x","journal-title":"Int J Hematol"},{"issue":"1","key":"6131_CR151","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3349\/ymj.2020.61.1.20","volume":"61","author":"L Chen","year":"2020","unstructured":"Chen L, Zhan CZ, Wang T, You H, Yao R (2020) Curcumin inhibits the Proliferation, Migration, Invasion, and apoptosis of diffuse large B-Cell lymphoma cell line by regulating MiR-21\/VHL Axis. Yonsei Med J 61(1):20\u201329. https:\/\/doi.org\/10.3349\/ymj.2020.61.1.20","journal-title":"Yonsei Med J"},{"unstructured":"Mirna Therapeutics Presents Interim Phase 1 Data on First-in-Class microRNA-34 mimic, MRX34, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. https:\/\/www.businesswire.com\/news\/home\/20141119005280\/en\/Mirna-Therapeutics-Presents-Interim-Phase-1-Data#:~:text=Mirna%20filed%20its%20first%20Investigational%20New","key":"6131_CR152"},{"issue":"1","key":"6131_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpch.16","volume":"9","author":"BZ Stanton","year":"2017","unstructured":"Stanton BZ, Hodges C, Crabtree GR, Zhao K (2017) A General non-radioactive ATPase assay for chromatin remodeling complexes. Curr Protoc Chem Biol 9(1):1\u201310 Published 2017 Mar 2. https:\/\/doi.org\/10.1002\/cpch.16","journal-title":"Curr Protoc Chem Biol"},{"key":"6131_CR154","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","volume":"78","author":"CR Clapier","year":"2009","unstructured":"Clapier CR, Cairns BR (2009) The biology of chromatin remodeling complexes. Annu Rev Biochem 78:273\u2013304. https:\/\/doi.org\/10.1146\/annurev.biochem.77.062706.153223","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"6131_CR155","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrc1273","volume":"4","author":"CW Roberts","year":"2004","unstructured":"Roberts CW, Orkin SH (2004) The SWI\/SNF complex\u2013chromatin and cancer. Nat Rev Cancer 4(2):133\u2013142. https:\/\/doi.org\/10.1038\/nrc1273","journal-title":"Nat Rev Cancer"},{"issue":"6489","key":"6131_CR156","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/370477a0","volume":"370","author":"H Kwon","year":"1994","unstructured":"Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MR (1994) Nucleosome disruption and enhancement of activator binding by a human SW1\/SNF complex. Nature 370(6489):477\u2013481. https:\/\/doi.org\/10.1038\/370477a0","journal-title":"Nature"},{"issue":"6","key":"6131_CR157","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C et al (2013) Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45(6):592\u2013601. https:\/\/doi.org\/10.1038\/ng.2628","journal-title":"Nat Genet"},{"issue":"26","key":"6131_CR158","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1182\/blood-2012-06-437624","volume":"120","author":"L Giulino-Roth","year":"2012","unstructured":"Giulino-Roth L, Wang K, MacDonald TY et al (2012) Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 120(26):5181\u20135184. https:\/\/doi.org\/10.1182\/blood-2012-06-437624","journal-title":"Blood"},{"issue":"4","key":"6131_CR159","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak K, Gomez F, White BS et al (2017) Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood 129(4):473\u2013483. https:\/\/doi.org\/10.1182\/blood-2016-07-729954","journal-title":"Blood"},{"issue":"5","key":"6131_CR160","doi-asserted-by":"publisher","first-page":"e202201770","DOI":"10.26508\/lsa.202201770","volume":"6","author":"N Dietrich","year":"2023","unstructured":"Dietrich N, Trotter K, Ward JM, Archer TK (2023) BRG1 HSA domain interactions with BCL7 proteins are critical for remodeling and gene expression. Life Sci Alliance 6(5):e202201770 Published 2023 Feb 17. https:\/\/doi.org\/10.26508\/lsa.202201770","journal-title":"Life Sci Alliance"},{"issue":"10","key":"6131_CR161","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41375-020-0919-5","volume":"34","author":"C Bali\u00f1as-Gavira","year":"2020","unstructured":"Bali\u00f1as-Gavira C, Rodr\u00edguez MI, Andrades A et al (2020) Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia 34(10):2722\u20132735. https:\/\/doi.org\/10.1038\/s41375-020-0919-5","journal-title":"Leukemia"},{"issue":"1","key":"6131_CR162","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS et al (2019) Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med 25(1):119\u2013129. https:\/\/doi.org\/10.1038\/s41591-018-0243-z","journal-title":"Nat Med"},{"issue":"7841","key":"6131_CR163","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","volume":"589","author":"N Yusufova","year":"2021","unstructured":"Yusufova N, Kloetgen A, Teater M et al (2021) Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature 589(7841):299\u2013305. https:\/\/doi.org\/10.1038\/s41586-020-3017-y","journal-title":"Nature"},{"issue":"7","key":"6131_CR164","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/ijms22073458","volume":"22","author":"M Scafuro","year":"2021","unstructured":"Scafuro M, Capasso L, Carafa V, Altucci L, Nebbioso A (2021) Gene transactivation and transrepression in MYC-Driven cancers. Int J Mol Sci 22(7):3458. https:\/\/doi.org\/10.3390\/ijms22073458. Published 2021 Mar 27","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6131_CR165","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2020007292","volume":"137","author":"HS Kuehn","year":"2021","unstructured":"Kuehn HS, Niemela JE, Stoddard J et al (2021) Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies. Blood 137(3):349\u2013363. https:\/\/doi.org\/10.1182\/blood.2020007292","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:16:06Z","timestamp":1735866966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":165,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6131"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06131-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}